Does Red Light Therapy Help Radiation Therapy Side Effects? (2026)

Radiation therapy remains one of the most effective cancer treatments, with approximately 50% of all cancer patients receiving radiotherapy at some point during their care. But its effectiveness comes at a cost — ionizing radiation does not discriminate perfectly between cancer cells and healthy tissue, and the collateral damage to normal cells produces side effects that can range from uncomfortable to debilitating.

Photobiomodulation (PBM) has emerged as one of the most evidence-backed supportive care interventions in oncology. Unlike many complementary therapies, PBM for radiation side effects has reached the highest level of evidence: inclusion in international clinical practice guidelines. The Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) recommend PBM for oral mucositis prevention, and growing evidence supports its use for radiation dermatitis, fibrosis, lymphedema, and fatigue.

How Radiation Damages Healthy Tissue

Understanding why PBM helps requires understanding how radiation causes side effects. Ionizing radiation damages cells through two pathways:

Direct DNA Damage

High-energy photons break DNA strands directly. While cancer cells are targeted, rapidly dividing healthy cells (mucosal lining, skin, bone marrow, hair follicles) are vulnerable because they cannot repair the damage as quickly as slowly dividing cells.

Indirect Damage via Reactive Oxygen Species

Radiation ionizes water molecules in tissue, creating hydroxyl radicals and other reactive oxygen species (ROS). These ROS cause oxidative damage to proteins, lipids, and DNA — triggering inflammatory cascades that persist long after treatment ends.

The result is a predictable pattern of side effects based on the treatment area:

Treatment Area	Common Side Effects	Onset	Duration
Head & neck	Oral mucositis, xerostomia, dysphagia, dermatitis	Week 2-3	Weeks to months post-treatment
Breast/chest	Radiation dermatitis, fibrosis, lymphedema	Week 2-4	Months to years (fibrosis)
Pelvis	Proctitis, cystitis, dermatitis, fatigue	Week 2-3	Weeks to months
Brain	Fatigue, cognitive changes, dermatitis	Week 1-2	Months to permanent
Any area	Fatigue, immune suppression	Week 1	Throughout and 4-8 weeks after

5 Mechanisms of PBM in Radiation Injury Recovery

PBM addresses radiation damage through mechanisms that directly counteract the biological effects of ionizing radiation:

1. Mitochondrial Rescue

Radiation damages mitochondria, reducing ATP production at a time when cells desperately need energy for repair. Red and near-infrared light restores cytochrome c oxidase function, increasing ATP output in damaged cells. This provides the energy substrate for DNA repair enzymes, protein synthesis, and cellular division needed to replace destroyed tissue.

2. Anti-Inflammatory Cytokine Modulation

Radiation triggers a sustained inflammatory cascade through NF-kB activation, producing TNF-alpha, IL-1beta, and IL-6. PBM modulates this response — reducing pro-inflammatory cytokines while preserving the controlled inflammation needed for healing. This is critical because the inflammatory overshoot is what causes much of the clinical severity of radiation side effects.

3. Enhanced Tissue Repair and Collagen Synthesis

PBM upregulates fibroblast proliferation and collagen synthesis — the building blocks of tissue repair. For radiation-damaged skin and mucosa, this means faster epithelial regeneration, better wound closure, and reduced risk of chronic ulceration.

4. Angiogenesis and Blood Supply Restoration

Radiation damages blood vessels, reducing perfusion to treated areas. PBM stimulates vascular endothelial growth factor (VEGF) expression and nitric oxide release, promoting new blood vessel formation and improving blood flow to ischemic tissue. This is particularly important for late effects like fibrosis and osteoradionecrosis.

5. Pain Modulation

PBM reduces pain through multiple pathways: decreased inflammatory mediators at the injury site, modulation of nerve conduction velocity, increased endorphin release, and reduced edema that puts pressure on nerve endings. For conditions like oral mucositis, where pain can prevent eating and speaking, this mechanism alone can significantly improve quality of life.

Oral Mucositis: The Strongest Evidence

Oral mucositis — painful inflammation and ulceration of the mouth and throat lining — is the most studied application of PBM in oncology, and the evidence is strong enough to warrant guideline-level recommendations.

The Clinical Problem

Mucositis affects up to 80% of head and neck cancer patients receiving radiation, and 40% of patients receiving high-dose chemotherapy. Severe mucositis (Grade 3-4) causes:

• Pain requiring opioid analgesia
• Inability to eat or drink, often necessitating feeding tube placement
• Treatment interruptions or dose reductions that compromise cancer outcomes
• Hospitalization for fluid management and pain control
• Risk of secondary infection from mucosal barrier breakdown

Key Clinical Evidence

Antunes et al. (2017, Oral Oncology, PMID:28688677): The underlying phase III randomized, double-blind, placebo-controlled trial (Antunes 2013, PMID:24044799) enrolled 94 patients with oropharyngeal, nasopharyngeal or hypopharyngeal cancer and found that intraoral 660nm laser PBM, applied by a clinician before each chemoradiation session, reduced Grade 3-4 mucositis from 40.5% to 6.4% (RR 0.158, 95% CI 0.050-0.498). The 2017 long-term follow-up of those same 94 patients (median 41.3 months) reported a higher complete response rate with PBM (89.1% vs 67.4%, p=0.013) and better progression-free survival (61.7% vs 40.4%, p=0.030); overall survival was not significantly different (57.4% vs 40.4%). The trial never measured tumor recurrence rates, so it cannot be cited as showing "no increase in recurrence" — what it shows is no signal of worse cancer outcomes in one 94-patient trial whose own authors called for larger studies.

Oberoi et al. (2014, PLoS ONE, PMID:25198431): Meta-analysis of 18 randomized controlled trials (n=1,144) found prophylactic low-level laser therapy reduced the overall risk of severe mucositis by roughly 63% (RR 0.37, 95% CI 0.20-0.67) and the incidence of severe pain by about 74% (RR 0.26, 95% CI 0.18-0.37). There was no "1.5 points on a 10-point pain scale" result; the -1.49 figure sometimes quoted is a standardized mean difference for overall mucositis grade, not a pain score.

MASCC/ISOO Guidelines (Elad et al. 2020, Cancer, PMID:32786044; underlying PBM systematic review Zadik et al. 2019, Supportive Care in Cancer, PMID:31286228): PBM was given a "Recommendation" grade — the strongest endorsement level — for preventing oral mucositis in three settings: high-dose chemotherapy stem cell transplant (Level of Evidence I), head and neck radiotherapy without chemotherapy (Level of Evidence II), and head and neck radiochemotherapy (Level of Evidence I). Two limits travel with that recommendation and are routinely dropped. First, it applies specifically to intraoral PBM delivered with the protocols listed in the guideline — an external light panel is not what was recommended. Second, MASCC/ISOO issued "No Guideline Possible" for treating established mucositis and for chemotherapy-only mucositis, because the evidence there was inadequate.

Oral Mucositis Protocol

• Wavelength: 632-660nm (red) most studied; some protocols add 810-850nm (NIR)
• Power density: 10-50 mW/cm²
• Dose: 1-6 J per point, 2-3 J/cm² total
• Timing: Begin on day 1 of radiation, continue throughout treatment, treat before each radiation session
• Application: Intraoral application to high-risk sites (buccal mucosa, tongue, floor of mouth, soft palate, oropharynx)
• Frequency: Daily during treatment (ideally immediately before radiation)

Radiation Dermatitis: Growing Evidence

Radiation dermatitis affects up to 95% of patients receiving external beam radiation. It ranges from mild erythema (redness) to moist desquamation (skin breakdown with weeping) and can cause significant pain and secondary infection risk.

Clinical Evidence

Censabella et al. (2016, Supportive Care in Cancer, PMID:27116013): The DERMIS study was a non-randomized pilot comparing two successive cohorts of breast cancer patients after lumpectomy (41 on standard skin care, 38 on standard skin care plus six laser sessions) — not a randomized controlled trial. Adding PBM was associated with less severe acute radiation dermatitis at the end of radiotherapy (3% vs 29% with RTOG grade 2 toxicity, p<0.005). Quality-of-life scores did not differ significantly between the groups, and duration of skin symptoms was not an outcome of this study.

Robijns et al. (2018, Lasers in Surgery and Medicine, PMID:29427390): The TRANSDERMIS randomized, placebo-controlled trial of 120 breast cancer patients showed PBM reduced the incidence of severe radiation dermatitis (RTOG grade 2 or higher: 6.7% with PBM vs 30% with placebo, p=0.004) and improved patient-reported quality of life scores.

Radiation Dermatitis Protocol

• Wavelength: 630-660nm (red) for superficial skin; 810-850nm (NIR) for deeper tissue layers
• Application area: Radiation field margins and surrounding at-risk skin (coordinate exact placement with radiation oncologist)
• Timing: Begin within the first week of radiation, continue throughout and 2-4 weeks post-treatment
• Duration: 10-15 minutes per treatment area
• Frequency: 3-5 times weekly during treatment

Radiation Fibrosis: Late Effect Management

Radiation fibrosis is a chronic late effect where irradiated tissue becomes thickened, stiff, and contracted due to excessive collagen deposition. It can develop months to years after treatment and is traditionally considered irreversible. PBM offers a potential intervention:

• PBM modulates transforming growth factor beta (TGF-β), a key driver of fibrosis
• Near-infrared wavelengths penetrate to deeper fibrotic tissue
• Improved microcirculation can help soften and remodel fibrotic tissue over time
• Several case series report measurable improvement in tissue pliability after sustained PBM treatment

Fibrosis Protocol

• Wavelength: 810-850nm (NIR) for deeper penetration
• Duration: 15-20 minutes over the fibrotic area
• Frequency: Daily for 8-12 weeks, then 3-4 times weekly for maintenance
• Expectations: Gradual improvement over months; complete reversal is unlikely but measurable softening and improved range of motion are achievable

Lymphedema After Radiation

Radiation-related lymphedema, particularly common after breast cancer treatment (affecting 20-40% of patients), responds to PBM through lymphatic vessel stimulation and anti-inflammatory effects. PBM has been studied specifically in breast cancer-related lymphedema (BCRL):

Smoot et al. (2015, Journal of Cancer Survivorship, PMID:25432632): A systematic review and meta-analysis of nine studies found moderate-strength evidence for low-level laser therapy in breast cancer-related lymphedema: a pooled within-group arm volume reduction of about 76 mL, and about 91 mL greater reduction than treatment without laser. Within-group pain fell by 13.5 mm on a 100 mm scale, but the between-group difference in pain was not statistically significant (ES -1.21, 95% CI -4.51 to 2.10). Combination with manual lymphatic drainage and compression was not tested as a comparison in this review.

Radiation-Induced Fatigue

Fatigue affects 70-100% of radiation patients and can persist for months after treatment ends. While the mechanism is multifactorial (inflammation, anemia, sleep disruption, psychological distress), the mitochondrial dysfunction component may respond to PBM:

• PBM restores mitochondrial ATP production in fatigued cells
• Systemic anti-inflammatory effects may reduce fatigue-promoting cytokines
• Improved sleep quality (through melatonin regulation) may indirectly improve fatigue

Evidence for this specific application is still emerging, but the biological rationale is strong and preliminary clinical observations are promising.

Supportive Care Comparison

Intervention	Target Side Effects	Evidence Level	Side Effects of Intervention
Photobiomodulation (PBM)	Mucositis, dermatitis, fibrosis, lymphedema, fatigue	Guideline-recommended (mucositis); strong (dermatitis); emerging (others)	None significant
Palifermin (Kepivance)	Oral mucositis	FDA-approved	Rash, edema, fever; very expensive
Cryotherapy (ice chips)	Oral mucositis (chemo-related)	Guideline-recommended	Discomfort; limited applicability
Topical steroids	Radiation dermatitis	Moderate	Skin thinning with prolonged use
Amifostine	Xerostomia	Guideline-recommended	Nausea, hypotension; IV administration
Hyperbaric oxygen	Osteoradionecrosis, fibrosis	Moderate	Barotrauma, claustrophobia; very expensive

Critical Safety Considerations

Does PBM Interfere with Radiation Treatment?

This is the most important safety question, and the honest answer is that no signal of harm has been identified — which is not the same as proven safe. The 2017 long-term follow-up of the Antunes trial found cancer outcomes were no worse in the PBM arm (complete response and progression-free survival were in fact higher), and a systematic review of 27 studies of PBM used for cancer-treatment toxicities found no tumor-safety issues (de Pauli Paglioni et al. 2019, PMID:31109692). Against that, a review written by PBM researchers themselves states that the impact of PBM on tumor behavior remains insufficiently studied, that in vitro results across cancer cell lines are conflicting, and that "vigilance remains warranted" (Zecha et al. 2016, PMID:26984240). All of this evidence comes from clinician-delivered protocols at specified parameters, and the foundational trials deliberately kept the tumor outside the light field (Bensadoun et al. 1999, PMID:10423050).

The biological explanation: PBM operates through photochemical mechanisms (cytochrome c oxidase activation at 1-50 mW/cm²), while radiation therapy operates through ionization at vastly higher energy levels. These are fundamentally different physical processes that do not interfere with each other.

Coordination with Oncology Team

Despite the safety data, always coordinate PBM use with your radiation oncologist and cancer care team:

• Get explicit approval before starting PBM during active treatment
• Discuss timing relative to radiation sessions (most protocols recommend PBM before radiation, not immediately after)
• Do not apply PBM directly over known tumor sites during active treatment as a precaution
• Report any unexpected skin reactions or changes
• Many cancer centers now have PBM protocols integrated into their supportive care programs

Home vs Clinical PBM for Cancer Patients

For oral mucositis, clinical-grade intraoral devices are typically needed — this is usually administered in the cancer center. For radiation dermatitis, fibrosis, lymphedema, and fatigue, home-based full-body panels can be effective:

• Clinical PBM: Precise intraoral application, higher power density, administered by trained staff. Essential for mucositis protocols
• Home panels (like Hale RLPRO): Appropriate for dermatitis management, fibrosis treatment, lymphedema support, fatigue management, and general recovery. FDA-listed, Health Canada Class II licensed (RLPRO 1200/2000), with verified wavelength output at 660nm and 850nm

The Bottom Line

Photobiomodulation has moved from experimental to guideline-recommended in oncology supportive care. For oral mucositis prevention, the evidence is strong enough that many cancer centers now offer it as standard care. For radiation dermatitis, fibrosis, and lymphedema, the evidence continues to grow and supports use as an adjunctive therapy.

If you are undergoing or recovering from radiation therapy, discuss PBM with your oncology team. This is one of the few supportive interventions that has essentially no side effects, does not interfere with cancer treatment, and has the evidence base to back up its use.

Frequently Asked Questions

Is red light therapy safe during cancer radiation treatment?

Photobiomodulation for radiation side effects has been extensively studied and is considered safe when used as a supportive therapy during radiation treatment. The Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) recommend photobiomodulation for preventing oral mucositis in patients undergoing head and neck radiation. However, direct application over active tumor sites is generally avoided, and treatment should be coordinated with the oncology team.

How does red light therapy help with radiation therapy side effects?

Red and near-infrared light reduce radiation-induced tissue damage by decreasing inflammation, promoting DNA repair in normal (non-cancerous) cells, stimulating stem cell activity for tissue regeneration, and enhancing wound healing in irradiated tissue. The most robust evidence exists for preventing and treating oral mucositis, radiation dermatitis (skin burns), and xerostomia (dry mouth). These benefits reduce treatment interruptions and improve patient quality of life during cancer therapy.

Can red light therapy help radiation burns heal faster?

Yes. Clinical studies show that photobiomodulation significantly accelerates healing of radiation dermatitis compared to standard skin care alone. The therapy reduces inflammatory mediators in irradiated skin, stimulates keratinocyte and fibroblast proliferation, and enhances collagen deposition for tissue repair. Treatment is typically applied directly to the irradiated skin area for 10–15 minutes daily, beginning at the first signs of skin reaction and continuing throughout the radiation course.

References

• Antunes HS, et al. Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis. Oral Oncology. 2017;71:11-15. PMID:28688677
• Antunes HS, et al. Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiotherapy and Oncology. 2013;109(2):297-302. PMID:24044799
• Oberoi S, et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107418.
• Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423-4431. PMID:32786044
• Zadik Y, Arany PR, Fregnani ER, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer. 2019;27(10):3969-3983. PMID:31286228
• Censabella S, Claes S, Robijns J, Bulens P, Mebis J. Photobiomodulation for the management of radiation dermatitis: the DERMIS trial, a pilot study of MLS laser therapy in breast cancer patients. Supportive Care in Cancer. 2016;24(9):3925-3933. PMID:27116013
• Robijns J, Censabella S, Claes S, et al. Prevention of acute radiodermatitis by photobiomodulation: a randomized, placebo-controlled trial in breast cancer patients (TRANSDERMIS trial). Lasers in Surgery and Medicine. 2018;50(7):763-771. PMID:29427390
• Bensadoun RJ, et al. Safety and efficacy of photobiomodulation therapy in oncology: a systematic review. Cancer Medicine. 2020;9(22):8279-8300.
• Smoot B, Chiavola-Larson L, Lee J, Manibusan H, Allen DD. Effect of low-level laser therapy on pain and swelling in women with breast cancer-related lymphedema: a systematic review and meta-analysis. Journal of Cancer Survivorship. 2015;9(2):287-304. PMID:25432632